Predictimmune is a molecular diagnostics company whose core IP predicts long-term disease outcome in immune-related diseases. The issue is that immune diseases are characterised by a high degree of disease heterogeneity and treatment is associated with high costs and severe side effects. Hence some patients may need aggressive treatment early and others may need to avoid it but there is no method to distinguish between these patients currently.
